Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IdeS in asymptomatic antibody-mediated TTP with low ADAMTS13 activity
2016-000249-30Phase 2Terminated
- Sponsor
- Hansa Biopharma
- Start
- May 2016
- Modality
- Therapeutic Enzymes → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of imlifidase in thrombotic thrombocytopenic purpura (TTP), sponsored by Hansa Biopharma. Primary endpoint: Safety and tolerability. Started May 2016; status: terminated.
02
Drugs
imlifidase
03
Conditions
thrombotic thrombocytopenic purpura (TTP)
Beyond the preview
Go deeper on 2016-000249-30.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-000249-30.